Marta Tonello1, Antonia Calligaro1, Maria Favaro1, Teresa Del Ross1, Paola Veronese2, Elisa Salvan3, Maria Teresa Gervasi2, Amelia Ruffatti4. 1. Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy. 2. Obstetrics and Gynecology Unit, Department of Woman's and Child's Health, University Hospital of Padua, Padua, Italy. 3. General Department, University of Padua, Padua, Italy. 4. Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy. amelia.ruffatti@unipd.it.
Abstract
PURPOSE: The long-term risk of thrombosis after pregnancy in women with purely obstetric antiphospholipid syndrome (OAPS) is not well defined. The current study's primary outcome was to evaluate the incidence and characteristics of the first thrombotic event in OAPS, identifying the risk factors for thrombosis in OAPS was its secondary one. METHODS: Patients with purely OAPS were consecutively enrolled between September 1999 and September 2019. Subjects without a history of pregnancy morbidity or thrombosis but with persistent positivity for one or more antiphospholipid antibodies (aPL carriers) made up the control group. The study groups included 94 OAPS patients and 124 aPL carriers who were matched for clinical and laboratory parameters. RESULTS: An event rate of 0.49/100 patient years was registered in OAPS patients during a mean follow-up of 8.7 years ± 5.5 SD. Kaplan-Meier survival analysis revealed that the cumulative incidence of thromboembolic events was not significantly different in OAPS patients vs aPL carriers. Arterial thrombosis and cerebrovascular events were the more frequent types of vascular involvement in the two groups. As far as risk factors for thrombosis were concerned, the presence of lupus anticoagulant significantly prevailed in both thrombotic OAPS patients and thrombotic aPL carriers with respect to purely OAPS patients and aPL carriers who did not develop thrombosis (p = 0.01 and p = 0.00, respectively). CONCLUSION: Just as for aPL carriers, closer monitoring and possibly, a pharmacological prophylaxis should be reserved for OAPS patients at highest risk of developing the first thrombotic event.
PURPOSE: The long-term risk of thrombosis after pregnancy in women with purely obstetric antiphospholipid syndrome (OAPS) is not well defined. The current study's primary outcome was to evaluate the incidence and characteristics of the first thrombotic event in OAPS, identifying the risk factors for thrombosis in OAPS was its secondary one. METHODS:Patients with purely OAPS were consecutively enrolled between September 1999 and September 2019. Subjects without a history of pregnancy morbidity or thrombosis but with persistent positivity for one or more antiphospholipid antibodies (aPL carriers) made up the control group. The study groups included 94 OAPS patients and 124 aPL carriers who were matched for clinical and laboratory parameters. RESULTS: An event rate of 0.49/100 patient years was registered in OAPS patients during a mean follow-up of 8.7 years ± 5.5 SD. Kaplan-Meier survival analysis revealed that the cumulative incidence of thromboembolic events was not significantly different in OAPS patients vs aPL carriers. Arterial thrombosis and cerebrovascular events were the more frequent types of vascular involvement in the two groups. As far as risk factors for thrombosis were concerned, the presence of lupus anticoagulant significantly prevailed in both thrombotic OAPSpatients and thrombotic aPL carriers with respect to purely OAPS patients and aPL carriers who did not develop thrombosis (p = 0.01 and p = 0.00, respectively). CONCLUSION: Just as for aPL carriers, closer monitoring and possibly, a pharmacological prophylaxis should be reserved for OAPS patients at highest risk of developing the first thrombotic event.
Authors: S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis Journal: J Thromb Haemost Date: 2006-02 Impact factor: 5.824
Authors: Amelia Ruffatti; Marta Tonello; Ariela Hoxha; Savino Sciascia; Maria J Cuadrado; José O Latino; Sebastian Udry; Tatiana Reshetnyak; Nathalie Costedoat-Chalumeau; Nathalie Morel; Luca Marozio; Angela Tincani; Laura Andreoli; Ewa Haladyj; Pier L Meroni; Maria Gerosa; Jaume Alijotas-Reig; Sara Tenti; Karoline Mayer-Pickel; Michal J Simchen; Maria T Bertero; Sara De Carolis; Véronique Ramoni; Arsène Mekinian; Elvira Grandone; Aldo Maina; Fátima Serrano; Vittorio Pengo; Munther A Khamashta Journal: Thromb Haemost Date: 2018-02-28 Impact factor: 5.249
Authors: Maria Angeles Martinez-Zamora; Sara Peralta; Montserrat Creus; Dolors Tassies; Juan Carlos Reverter; Gerard Espinosa; Ricard Cervera; Francisco Carmona; Juan Balasch Journal: Ann Rheum Dis Date: 2011-09-06 Impact factor: 19.103
Authors: G Lefèvre; M Lambert; J-L Bacri; S Dubucquoi; T Quemeneur; C Caron; D Launay; V Houfflin-Debarge; E Hachulla; X Kyndt; D Subtil; P-Y Hatron Journal: Lupus Date: 2011-05-05 Impact factor: 2.911
Authors: G R de Jesús; S Sciascia; D Andrade; M Barbhaiya; M Tektonidou; A Banzato; V Pengo; L Ji; P L Meroni; A Ugarte; H Cohen; D W Branch; L Andreoli; H M Belmont; P R Fortin; M Petri; E Rodriguez; R Cervera; J S Knight; T Atsumi; R Willis; I S Nascimento; R Rosa; D Erkan; R A Levy Journal: BJOG Date: 2018-10-24 Impact factor: 6.531